22.09.2011 • News • Bristol-Myers Squibb (BMS) • Ambrx

Bristol-Myers, Ambrx Team Up For Biologics Programs In Diabetes, Heart Failure

Bristol-Myers Squibb and Ambrx announced a collaboration under which Bristol-Myers will receive exclusive worldwide rights to research, develop and commercialize biologics based on Ambrx's research surrounding the Fibroblast Growth Factor 21, or FGF-21, protein, for potential use in treating type 2 diabetes, and the Relaxin hormone, for potential use in treating heart failure.

Derivatives of FGF-21 and Relaxin were developed using Ambrx's unique ReCODE platform technology to modify the native proteins with amino acid building blocks beyond the common 20 to engineer enhanced versions for investigation for therapeutic use.

As per the terms of the agreement, Bristol-Myers will make an upfront payment of $24 million to Ambrx. Bristol-Myers will also make potential milestone payments and royalty payments on worldwide sales for both programs. Besides, Bristol-Myers and Ambrx will enter research collaborations for both programs.

Free Virtual Event

Bioprocess Forum

Vaccine Manufacturing

Join global experts and innovators for a two-day virtual event exploring the latest breakthroughs and best practices in vaccine manufacturing. Discover how new technologies and process innovations are shaping the future of vaccine production, safety, and scalability.

Whitepaper

Setting the Standard

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)

Are you ready to elevate your pharmaceutical operations? Download our exclusive whitepaper and discover how compliance with Good Distribution Practice (GDP) is essential for the safety and integrity of pharmaceuticals.